5-Alpha Reductase Inhibitors and the Risk of Anemia Among Men With Benign Prostatic Hyperplasia: A Population-Based Cohort Study

The study examined the risk of anemia in men with benign prostatic hyperplasia (BPH) using 5-α reductase inhibitors (5αRIs) compared to α-blockers, involving 62,380 patients. It found no increased risk of anemia with 5αRIs, with a hazard ratio of 0.95, indicating a slightly lower risk that was not statistically significant. The study's robust methodology, including propensity-score matching and sensitivity analyses, supported the reliability of these findings, providing reassurance about the safety of 5αRIs concerning anemia in this population.